参松养心胶囊联合沙库巴曲缬沙坦钠片治疗慢性心力衰竭合并室性心律失常的临床研究  

Clinical Study of Shensong Yangxin Capsule Combined with Sacubitril Valsartan Sodium Tablets in the Treatment of Chronic Heart Failure with Ventricular Arrhythmia

作　　者：蒋兆年[1] 秦卓 韩磊[3] JIANG Zhaonian;QIN Zhuo;HAN Lei(Nanyuan Hospital,Fengtai District,Beijing,Beijing 100076,China)

机构地区：[1]北京市丰台区南苑医院,北京100076 [2]北京博爱医院 [3]北京航天总医院

出　　处：《中外医学研究》2021年第5期66-68,共3页CHINESE AND FOREIGN MEDICAL RESEARCH

摘　　要：目的:分析应用参松养心胶囊联合沙库巴曲缬沙坦钠片治疗慢性心力衰竭合并室性心律失常的临床效果。方法:选取2017年1月-2019年12月,本院收治的慢性心力衰竭合并室性心律失常患者60例,随机分为对照组和试验组,每组30例。给予对照组沙库巴曲缬沙坦钠片治疗,给予试验组参松养心胶囊联合沙库巴曲缬沙坦钠片治疗。比较两组临床疗效。结果:试验组与对照组总有效率分别为96.67%、70.00%,差异有统计学意义(P<0.05);试验组LVEF(43.62±3.98)%及CO(4.63±0.39)L/min,显著高于对照组的(39.98±3.56)%及(4.09±0.35)L/min,差异有统计学意义(P<0.05);试验组LVEDD(59.20±3.33)mm,显著低于对照组的(61.32±3.45)mm,差异有统计学意义(P<0.05);试验组ADH(60.87±3.87)ng/L、PRA(3.28±0.44)μg/(L·h)及NT-proBNP(2 140.34±103.23)ng/L,显著低于对照组的(73.31±4.00)ng/L、(3.70±0.51)μg/(L·h)及(2 590.43±114.43)ng/L,差异有统计学意义(P<0.05);试验组血清钠(143.41±25.43)mmol/L,显著高于对照组的(134.32±24.42)mmol/L,差异有统计学意义(P<0.05)。结论:参松养心胶囊联合沙库巴曲缬沙坦钠片治疗慢性心力衰竭合并室性心律失常患者效果显著,具有较高的临床应用价值。Objective:To analyze the clinical effects of Shensong Yangxin Capsule combined with Sacubitril Valsartan Sodium Tablets in the treatment of chronic heart failure with ventricular arrhythmia.Method:From January 2017 to December 2019,60 patients with chronic heart failure and ventricular arrhythmia admitted to our hospital were selected and randomly divided into the control group and the experimental group with 30 cases in each group.The control group was treated with Sacubitril Valsartan Sodium Tablets,and the experimental group was treated with Shensong Yangxin Capsule combined with Sacubitril Valsartan Sodium Tablets.The clinical treatment effects of two groups were compared.Result:The total effective rates of the experimental group and the control group were 96.67%and 70.00%respectively,the difference was statistically significant(P<0.05).The LVEF of the experimental group was(43.62±3.98)%and CO was(4.63±0.39)L/min,which were significantly higher than(39.98±3.56)%and(4.09±0.35)L/min of the control group,the differences were statistically significant(P<0.05).The LVEDD of the experimental group was(59.20±3.33)mm,which was significantly lower than(61.32±3.45)mm of the control group,and the difference was statistically significant(P<0.05).The experimental group’s ADH(60.87±3.87)ng/L,PRA(3.28±0.44)μg/(L·h)and NT-proBNP(2140.34±103.23)ng/L were significantly lower than(73.31±4.00)ng/L,(3.70±0.51)μg/(L·h)and(2590.43±114.43)ng/L of the control group,the differences were statistically significant(P<0.05).The serum sodium(143.41±25.43)mmol/L of the experimental group was significantly higher than(134.32±24.42)mmol/L of the control group,the difference was statistically significant(P<0.05).Conclusion:Shensong Yangxin Capsule combined with Sacubitril Valsartan Sodium Tablets is effective in treating patients with chronic heart failure complicated with ventricular arrhythmia,and has high clinical application value.

关 键 词：参松养心胶囊 沙库巴曲缬沙坦钠片 慢性心力衰竭 室性心律失常 

分 类 号：R541.6[医药卫生—心血管疾病] R541.7[医药卫生—内科学]